Z-0083-2022 Class II Ongoing

Recalled by Roche Molecular Systems, Inc. — Branchburg, NJ

FDA device recall Z-0083-2022 was initiated by Roche Molecular Systems, Inc. on September 3, 2021 and is designated Class II. Reason for recall: False Mutation Detected results for the exon 20 insertion (Ex20Ins) mutation when using the cobas EGFR Mutation Test v2, may lead to inappropriate treatment The recall status is ongoing. Affected quantity: 507 US; 6,676 ex- US.

Recall Details

Product Type
Devices
Report Date
October 20, 2021
Initiation Date
September 3, 2021
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
507 US; 6,676 ex- US

Product Description

cobas EGFR Mutation Test v2-Somatic gene mutation detection system Catalog Number :07248563190

Reason for Recall

False Mutation Detected results for the exon 20 insertion (Ex20Ins) mutation when using the cobas EGFR Mutation Test v2, may lead to inappropriate treatment

Distribution Pattern

Worldwide distribution - US Nationwide distribution and the countries of Canada, UK, Poland, Spain, Italy, Sweden, Greece, Denmark, Norway, Netherlands, France, Czech Republic, Belgium, Austria, Slovakia, Hungary, Switzerland, Lithuania, Slovenia. Serbia, North Macedonia, Myanmar, Lebanon, Russia, Croatia, Morocco, Kazakhstan, Dominican Republic, Israel, El Salvador, Vietnam, Malaysia, Taiwan, China, Japan, Hong Kong, Korea, Brazil, Philippines, Thailand, Chile, Colombia, Singapore, Argentina, Australia, India, Uruguay, Ecuador, Panama, Costa Rica, Pakistan, Peru, Indonesia, New Zealand.

Code Information

All lot numbers